Tailored smartphone messages to help Cambodians with HIV quit smoking
Ending Tobacco Use through Interactive Tailored Messaging for Cambodian People Living with HIV/AIDS (EndIT)
A smartphone program that sends personalized messages and offers medications to help adults living with HIV in Cambodia stop smoking.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11401633 on NIH RePORTER |
What this research studies
You would receive interactive, tailored messages on your smartphone designed to support quitting, along with pharmacologic treatment when appropriate. The program combines behavioral messaging and medication and is delivered automatically through an mHealth platform that the team already piloted in Cambodia. People will be randomly assigned to the messaging-plus-medication approach or a comparison group so researchers can see which helps more people quit. Study staff will follow participants over time while they continue their HIV care to track smoking and health outcomes.
Who could benefit from this research
Good fit: Adults (21 years and older) living with HIV in Cambodia who currently smoke cigarettes and are receiving antiretroviral therapy are the ideal candidates.
Not a fit: People who do not smoke, are younger than 21, are not located in Cambodia, lack smartphone access, or decline medications or messaging support are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this approach could help more people with HIV in Cambodia quit smoking and improve their long-term health and survival.
How similar studies have performed: Similar smartphone and text-message programs have shown promise for helping smokers quit in higher-income countries and a small Cambodian pilot demonstrated feasibility, but larger trials are needed to confirm effectiveness.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Vidrine, Damon J. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Vidrine, Damon J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.